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Abstract 
Purpose 
We performed a multi-centre phase I study to assess the safety, pharmacokinetics and 
pharmacodynamics of the orally available small molecule MEK 1/2 inhibitor WX-554, and to 
determine the optimal biological dose for subsequent trials. 
Experimental design 
Patients with treatment-refractory, advanced solid tumours, with adequate performance 
status and organ function were recruited to a dose escalation study in a standard 3+3 
design. The starting dose was 25 mg orally once weekly with toxicity, pharmacokinetic (PK) 
and pharmacodynamics (PD) guided dose escalation with potential to explore alternative 
schedules. 
Results  
Forty-one patients with advanced solid tumours refractory to standard therapies and with 
adequate organ function were recruited in 8 cohorts up to doses of 150 mg once weekly and 
75 mg twice weekly. No dose limiting toxicities (DLTs) were observed during the study and a 
Maximum Tolerated Dose (MTD) was not established. The highest dose cohorts 
demonstrated sustained inhibition of ERK phosphorylation in PBMC peripheral blood 
mononuclear cells following ex vivo phorbol 12-myristate 13-acetate (PMA) stimulation. 
There was a decrease of 70 ± 26 % in mean phosphorylated (p)ERK in C1 Day 8 tumour 
biopsies when compared with pre-treatment tumour levels in the 75 mg twice a week 
cohort. Prolonged stable disease (> 6 months) was seen in 2 patients, one with cervical 
cancer and one with ampullary carcinoma. 
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Conclusions 
WX-554 was well tolerated and an optimal biological dose was established for further 
investigation in either a once or twice weekly regimens. The recommended phase 2 dose is 
75 mg twice weekly. 
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Introduction 
The RAS/RAF/MEK/ERK pathway is one of the major signal transduction pathways that 
controls cell proliferation and survival [1]. In preclinical studies, constitutive activation of the 
pathway has been shown to promote cellular transformation to an oncogenic phenotype 
[2].  Nearly a third of all cancers have a constitutively-active MAPK pathway and numerous 
upstream mutations in and/or over-expression of growth factor receptors, such as RAS and 
RAF, lead to activation of the MEK pathway. Clinical development of MEK inhibitors has 
focused to date on BRAF mutated disease including malignant melanoma, papillary thyroid 
cancer, ovarian cancer and colorectal cancer [3].  
 
MEK inhibitors are efficacious in multiple xenograft models where the MAPK pathway is 
activated [4, 5]. Moreover, MEK inhibitors in clinical trials have demonstrated anti-tumour 
activity as monotherapy [6], ]as well as a synergistic or additive efficacy with cytotoxics and 
other targeted drugs, particularly BRAF inhibitors [7-9].  
 
WX-554 is an oral small molecule allosteric inhibitor targeting mitogen-activated protein 
kinase kinase (MEK1 and MEK2) with an estimated IC50 of 4.7 nM and 10.7 nM respectively. 
A previous dose escalation study in healthy volunteers showed prolonged inhibition of MEK 
for over 72 hours following a single dose at all dose levels explored, with minimal toxicity 
encountered at doses <100 mg, and a maximum tolerated dose was not reached. 
Bioavailability was good with an estimated absorption of >80% and minimal impact of food 
on absorption. This study is the first in advanced cancer patients and aimed to define a safe, 
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well-tolerated and pharmacodynamically-active oral dosing regimen of WX-554 to be taken 
forward into Phase II studies. 
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Methods 
Study design 
A Phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetic 
profile, pharmacodynamic activity and anti-tumour activity of the MEK inhibitor WX-554 
was undertaken in five clinical centres in the United Kingdom between March 2012 and 
March 2014 (EudraCT No: 2011-003408-19). All patients gave written informed consent 
prior to undergoing any study-related procedures and the study was approved by an 
independent ethics committee and by the study centres. The study was performed 
according to ICH-GCP guidelines. The primary objective of the study was to determine the 
optimum biological dose (OBD) and the MTD, or the MTD alone if observed before the OBD.  
Eligible patients recruited were age ≥ 18 years old with advanced, metastatic solid tumours 
for whom no effective standard therapy was available. Patients had to have an Eastern 
Cooperative Oncology Group Performance Status (ECOG PS) less than or equal to 2, a life 
expectancy of more than three months and adequate organ function. Additional exclusion 
criteria included previous treatment with a MEK inhibitor, untreated or unstable brain 
metastases; past history of retinal vein occlusion, intraocular pressure > 21 mm Hg or 
patients considered at risk of retinal vein thrombosis. Slit lamp examinations were 
performed when clinically indicated at any point over the course of the study. 
 Sequential cohorts in a 3+3 design of at least 3 and up to 6 patients were enrolled, with 
each evaluable patient receiving at least one cycle of WX-554. The initial dose and schedule 
(informed by the findings of the healthy volunteers study) was 25mg orally on Days 1, 8 and 
15 of a 21-day cycle, and in the absence of DLTs, doses could be escalated by up to 100% 
between cohorts until the OBD and/or MTD was reached. Tumour burden was assessed 
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radiologically prior to therapy and every 2 cycles thereafter according to RECIST 1.1 [10]. 
Patients could continue to receive WX-554 until disease progression or withdrawal due to 
toxicity. 
Patients were seen weekly whilst on study and toxicity graded for severity based on the 
National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 
(NCI CTCAE v4.03). Full blood count, routine biochemistry, liver and coagulation profile were 
checked weekly during cycle 1 and at the start of each subsequent cycle.  The following 
were considered DLTs ; Grade 3/4 non-haematologic toxicity, excluding inadequately 
treated nausea, vomiting or diarrhoea; ≥ Grade 3 neutropenia of clinically significant 
duration, or associated with fever; Grade 4 thrombocytopenia or thrombocytopenia with 
clinically significant  bleeding; a delay in a scheduled dose of WX-554 of  >14 days due to 
toxicity.  If a single DLT event was observed, subsequent dose escalations were not to 
exceed 33% of the previous dose. If two or more DLTs occurred in a given cohort of up to 6 
patients, the next lower dose level was declared the MTD. All dose escalation steps and 
dose schedule recommendations were made by a Cohort Review Committee (CRC) who 
reviewed all available adverse events, pharmacokinetics, pharmacodynamics and other 
relevant patient data. The CRC could recommend exploration of alternative doses and 
schedules of WX-554 to maximise target inhibition with acceptable tolerability.   
The OBD was defined as the highest dose to attain maximal target inhibition, utilising a 
validated PD assessment of pERK in PBMCs and tumour biopsies at a tolerable dose.   
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Pharmacodynamic assessments 
Phosphorylation of ERK1/ERK2 was measured in circulating PBMCs following ex-vivo 
incubation with PMA. An 8 ml volume of whole blood was collected into a CPT vacutainer 
(BD, Oxford, UK) containing Sodium-Heparin during cycle 1 on day 1 and day 8 at  0, 1, 2, 4, 
6, and 24 hours relative to the time of drug administration. Additional pre-dose samples 
were taken at day 15 and at day 1 of subsequent cycles. The tubes were centrifuged at 
1,638g for 20 minutes to separate the PBMCs and plasma from other cellular contents and 
this fraction was decanted into a 15 ml Falcon tube (BD, Oxford, UK) for incubation with 500 
nM PMA (Sigma, Dorset, UK) for 20 minutes at 37°C. After two PBS washes the cells were 
pelleted and re-suspended in 1 ml of a lysis buffer containing 10 g/ml leupeptin, 10 g/ml 
pepstatin, 100 M phenylmethanesulfonylfluoride (PMSF), 3 g/ml aprotinin, 2.5 mM 
sodium pyrophosphate, 1 mM sodium orthovanadate, 6 M Urea, 1 mM 
ethylenediaminetetraacetic acid (EDTA), 0.5% Triton X 100, 5 mM sodium fluoride in 
phosphate buffered saline (PBS) (all from Sigma, Dorset, UK), pH 7.4. Lysis was carried out 
for 15 minutes on ice and lysate was store at -20oC prior to analysis. 
Phospho-ERK in the PBMC lysates was measured by a commercially available ELISA kit 
according to manufacturer’s instructions (R&D Systems, Oxford, UK).  
Absorbance was read at 450-590 nm and the concentration interpolated from a 2nd order 
polynomial curve over the range 20,10,5,3,2,1 and 0.5 ng/ml pERK. In parallel the protein 
concentration of the lysates was determined by the BCA assay (Thermo Scientific, 
Cramlington, UK). The final pERK1/2 concentration of the lysates was expressed as the ratio 
of the C1D1 sample after correcting for protein concentration. 
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Total and phosphorylated AKT, GSK3, P70S6K and ERK 1/2 in lysates from frozen tumour 
biopsies were measured using the electrochemiluminescent assays validated to good clinical 
practice standards on the Meso Scale Discovery (MSD) platform (MSD, Rockville, USA).  
Phosphorylated residues detected were Ser473 AKT, Ser9 GSK3, Thr421/Ser424 P70S6K, 
Thr202/204 ERK1 and Thr185/187 ERK2.  Protein concentrations of the tumour lysates were 
determined by BCA assay prior to analysis to allow known concentrations of lysate to be 
analysed.  Values of phosphorylated protein were expressed as a percentage of the 
phosphorylated protein levels before administration of WX-554, normalised to total protein 
(expressed as a percentage of pre-administration total protein levels) for each analyte.  
 
Pharmacokinetic Studies 
The concentration of WX-554 in plasma was measured in all patients in cycle 1 on day 1 and 
day 8 at 0, 1, 2, 4, 6, 8, 10 and 24 hours, and before dosing on day 1 of each subsequent 
cycle. Measurement was by an LC-MS/MS method developed and validated by Wilex  AG 
(Munich, Germany) on an API 3200 with Shimadzu LC-10ADvp HPLC. After solid phase 
extraction of 60 l plasma on an Oasis WCX plate and elution with 2 x 250 l 2% formic acid 
in methanol, the samples were evaporated to dryness and re-suspended in 100 µl 
acetonitrile/methanol (25/75). A 10 l volume (equivalent of 6 l plasma) was injected onto 
an Atlantis HILIC, 2.1 x 50mm, 3 m column (Waters, Eschborn, Germany). Mobile phase 
was: A, 10mM ammonium formate, pH3.8/acetonitrile (95/5 v/v) and B, 10mM ammonium 
formate, pH3.8/acetonitrile (5/95 v/v).  Elution occurred over a 2 minute gradient from 
10:90 A:B to 60:40 A:B. WX-554 was eluted at 1.5 minutes. Upper and lower limits of 
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quantification were 1000 and 1 ng/ml respectively. Both intra-assay and inter-assay co-
efficient of variation (CV) were <4% for all QC samples analysed. 
Pharmacokinetic parameters were calculated from drug concentrations in plasma vs. time 
curves using Phoenix WinNonlin version 6.2 (Certara, Princeton, USA) non-compartmental 
analysis. 
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Results 
Patient demographics are shown in table 1. A total of 41 patients were recruited into the 
study.  With a median age of 63 years (range 36-77 years), the population was mainly male 
(68%) and colorectal cancer was the most common solid tumour type.  One patient 
developed fatal bronchopneumonia before dosing with WX-554 and an additional patient 
was recruited to the study. Weekly dosing (QWK) was explored in 5 cohorts with doses from 
25 to 150 and twice-weekly dosing (BIS) in 3 cohorts with doses of 25 to 75 mg (Table S1).    
 
Safety 
WX-554 was generally well tolerated, with the majority of adverse reactions being CTCAE 
Grade 1 or 2.  A total of 489 adverse events were recorded with each of the 41 participants 
experiencing at least one AE and 33 (80.5%) had AEs considered to be related to WX-554. A 
total of 47 adverse event resulting in 30 incidents of dose delay or reduction were recorded 
in 12 patients over the course of the study. Of these 47 incidents 18 (38.3%) were 
considered to be possibly or probably related to study drug. Incidence of dose delay or 
reduction did not correlated with dose (Figure S1). Fatigue and diarrhoea were the most 
common adverse reactions followed in order of decreasing frequency by skin reactions, 
decreased appetite and nausea (Table 2).  When evaluated by cohort (Table S2) the 
incidence of treatment-related AE generally increased with dose and no clear differences in 
the incidence of toxicity were observed between the 75 mg BIS and 150 mg QWK schedules. 
However, fatigue was more  common in the 75 mg BIS cohort (78% compared with 57% in 
the 150 mg QWK cohort) with  and diarrhoea more frequent in the 150 mg QWK than in the 
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75 mg BIS (71 and 22 % respectively). No dose-limiting toxicities were recorded during the 
study and the MTD was not reached.    
In the absence of significant toxicity pharmacokinetic and pharmacodynamic data was used 
to inform dose decision making.  PK data closely mirrored that in healthy volunteers, and 
PK/PD modelling suggested that a longer duration of maximal inhibition might be achieved 
with twice weekly dosing.  Therefore from the 75mg dose level, the twice weekly dosing was 
explored in parallel, for safety reasons this was at one cumulative dose level behind the 
weekly dosing. 
Four potentially drug-related serious adverse events (SAEs) were observed and these all 
occurred at higher doses. These were sigmoid bowel perforation at a site of known disease 
(75 mg QWK at day 15), Grade 3 transaminitis (100mg QWK at day 47), Grade 4 anaemia 
(150 mg QWK at day 63) and Grade 2prolongation of QTc interval (75 mg BIS at day 15). 
Treatment was discontinued in the patients with bowel perforation and prolonged QTc; the 
other patients were re-challenged at a lower dose and tolerated treatment well.  Despite 
these events being either not definitively related to the study drug or occurring outside the 
formal DLT window each of these respective cohorts was expanded to 6 evaluable patients 
to ensure safety of any recommended dose.  
 
Pharmacodynamic effects 
Inhibition of ERK phosphorylation in ex vivo PMA-stimulated PBMCs was observed from the 
first dose level explored (Figure 1). Within the cohorts treated once weekly, maximum 
inhibition of ERK phosphorylation was seen at 4 or 6 hours, with recovery towards basal 
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levels seen at day 2 and 8 (Figure 1a). In cohorts 1, 2, 3 & 5, the mean maximum inhibition 
at 6 hours post administration on day 8, was 73 ± 5 %. The average degree of inhibition seen 
in the day 8 pre administration samples was 2 ± 18 %. In contrast, at the highest dose 
explored (150 mg QWK), the maximal degree of inhibition was 92 % and residual inhibition 
was observed in the day 8 pre administration sample (69 %). In the twice weekly cohorts 
there was a clear dose/PD relationship in the inhibition of ERK phosphorylation (Figure 1b). 
Following administration of 75 mg BIS pERK was inhibited 60% in the day 8 pre samples and 
70% in the 6 hour samples at day 8. 
Five paired tumour biopsies were available in cohort 8 (75 mg twice weekly), taken at the 
time of screening and at day 8. Biopsies were taken from liver metastases in 3 of the 
patients with primary CRC, pancreatic or cholangiocarcinoma; from right axillary lymph node 
from a separate patient with cholangiocarcinoma; and from a colorectal lung metastasis. 
Following homogenisation, tumour lysates were analysed using MSD 
electrochemiluminescent assays for the modulation of kinase signalling pathways. There 
was no change in the phosphorylation of AKT, GSK3 or P70S6K (all used as markers of PI3K 
pathway inhibition), between the pre-treatment and C1D8 biopsies (Figures 2a, b &c).  
In contrast, pERK signal was lower in 5/5 paired biopsies with a median decrease of 68 % 
(range, 30-95 %) as a ratio of total ERK at day 8 of cycle one compared with the screening 
biopsy. 
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Pharmacokinetics 
Pharmacokinetic parameters in all the cohorts are shown in Table 3. Mean exposure for 
each cohort over 24 hours following administration of cycle 1 on day 1 is shown in Figure 3. 
Individual concentration-time curves for each patient on day 1 and day 8 are shown in 
Figure S2. The drug appeared to be well absorbed with an average Tmax of 4.9 hours 
independent of dose with a mean half-life of 28 hours following all doses on day 1. Dose 
proportionality was observed between 25 and 75 mg administration, however, the once 
weekly administration of 150 mg resulted in greater variation in AUC. The mean 
concentration at 24 hours in the 150 QWK cohort was greater than the mean peak 
concentration in the 100 QWK cohort (figure 3a), and this was reflected in the degree of 
pERK inhibition at the 24 hour time point of the 150 QWK cohort also being greater than 
that seen in the peak inhibition of the 100 QWK cohort (figure 1a). 
 
Efficacy 
34 patients completed ≥ 6 weeks of dosing with WX-554 and were eligible for response 
assessment. No objective responses were observed, however 20 (59%) of participants had 
stable disease and two patients (6%) had prolonged disease stabilisation.  
A 54 year old woman with cervical cancer and locally advance pelvic disease had disease 
control for 10 cycles (over 30 weeks) at a dose of 75 mg QWK. Recruitment followed three 
previous lines of therapy including chemorad with cisplatin, five cycle of carboplatin and 
paclitaxel, and participation in a phase I trial of an IGFR inhibitor. A second case of 
prolonged stable disease was observed in a 66 year old woman with ampullary carcinoma 
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and lung metastases, previously treated with Gemcitabine and Cisplatin, who had controlled 
disease for 16 cycles (i.e. over 48 weeks) at a dose of 75 mg BIS.  
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Discussion 
This study shows that WX-554 is very well tolerated, with favourable pharmacokinetic 
characteristics, and that pharmacodynamically-active concentrations are achievable.  No 
definite dose-limiting toxicities were observed and therefore a MTD was not identified. 
However, a dosing regimen of 75 mg BIS for an expansion cohort was identified as an 
optimal biological dose (OBD) based on maximal observed inhibition of ERK phosphorylation 
in PMA-stimulated PBMCs and 70% decrease in pERK/ERK in tumour lysates at the day 8 
trough.  While the maximum pERK inhibition in PBMCs was greater in the 15O mg cohort 
than in the 75 mg twice weekly cohort it was felt that a more sustained inhibition was seen 
in the 75 mg twice weekly cohort. As well as the more sustained pERK inhibition it was felt 
that the PK properties of the 75 mg twice weekly schedule were preferable given the 
greater variation in exposure in the 150 mg cohort compared to the others. The intermittent 
weekly or BIS schedules had been identified as providing the optimal therapeutic window in 
preclinical studies.  Although other schedules might also be beneficial, this regimen is 
supported by the sustained pharmacodynamic effect. 
The use of MEK inhibitors in cancer chemotherapy has been the subject of clinical research 
for more than 10 years. Initial studies suffered from poor efficacy, which has been 
attributed to a lack of selection of patients with demonstrated oncogenic lesions of the 
MAPK pathway, poor pharmacokinetic properties and narrow therapeutic window, leading 
to dose reduction and treatment interruptions [11]. More recently, development of both a 
new generation of MEK inhibitors with better PK properties and enrichment for patients 
more likely to benefit has led to successes in the clinical utility of MEK inhibition. This has 
culminated in the approval of trametinib as a first line option in the treatment of BRAF 
mutated melanoma [6, 8] and of cobimetinib for use in combination with vemurafenib for 
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the treatment of adult patients with unresectable or metastatic melanoma with a BRAF 
V600 mutation [12]. 
However, the introduction of kinase inhibitors and biological agents targeting kinase 
signalling pathways has led to the observation of new toxicities in oncology clinics, 
particularly the skin and ocular problems resulting from inhibition of the MAPK pathway. 
The toxicity profile of WX-554 had similarities to that of other MEK inhibitors, with fatigue, 
diarrhoea, and dermatological reactions being the most frequent adverse reactions [13-18]. 
However, rash was not as frequently seen as with other MEK inhibitors, with any rash being 
seen in 27.5% of participants and maculo-papular rashes in just three participants (7.5%). 
Ocular toxicity was not reported in any patients.  The case of grade 4 anaemia in a patient 
treated with the highest dose was possibly drug related and the patient recovered and 
continued on study at a reduced dose. It is unknown at present if this is an off target effect 
of the drug though this must be considered a possibility in light of haematotoxicity not being 
seen with other MEK inhibitors. No severe anaemia was seen at the lower dose 
recommended for subsequent development. The likelihood that other adverse reactions 
seen during MEK inhibitor therapy are related to mechanism of action means that clinical 
regimens will have to include development of novel management protocols. Using quality of 
life measures, trametinib is reported to be better tolerated than standard chemotherapy 
[19], although this was in an open label study and may not reflect tolerance of prolonged 
therapy. 
The mean half-life of 28 hours of WX-554 is longer than that of most MEK inhibitors 
currently undergoing clinical investigations, with the exception of trametinib [15] and the 
dual RAF/MEK inhibitor RO5126766 [18].  This long half-life permitted the investigation of 
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both weekly and then twice weekly dosing schedules. When comparing the two cohorts 
given a cumulative weekly dose of 150 mg (150 QWK and 75 BIS), the AUC24h was 
proportionally greater than expected in the 150 QWK cohort compared to the 75 BIS cohort 
on both day 1 (993.0 ± 492.1 h*ng/ml and 276.0 ± 127.9 h*ng/ml respectively) and day 8 
(1129.8 ± 544.7 h*ng/ml and 320.4 ± 150.7 h*ng/ml respectively). While this greater 
exposure with the once weekly schedule was not associated with a higher incidence of 
adverse events, there was no indication that it conferred greater efficacy and the inhibition 
of pERK phosphorylation appeared to be less sustained than that observed in the 75 mg BIS 
cohort. 
Numerous other early phase clinical trials have reported modulation of pERK in surrogate 
and tumour tissues following administration of MEK inhibitors [13-15, 20]. However, 
differences in assays, tissues and time points used make direct comparisons problematic.  It 
is not known if the magnitude of the sustained pERK inhibition in a surrogate tissue 
correlates with either efficacy or mechanism-related toxicity. However, the magnitude of 
inhibition seen in the paired tumour biopsies indicates on target inhibition. No objective 
responses were observed in this heavily pre-treated population and any demonstration of 
efficacy must be determined in subsequent phase II and phase III trials. The lack of efficacy 
in this heavily pre-treated population may be partially attributable to lack of selection based 
on mutational analysis. Phase II and III trials of single agent trametinib have suggested 
efficacy in patients with BRAF-mutated melanoma who had not received previous BRAF 
inhibitor therapy [6] but not in those patients resistant to BRAF inhibition. In contrast, a 
series of phase II studies of other MEK inhibitors have shown limited evidence of efficacy in 
numerous settings, including treatment of cancers with high known incidence of 
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dysregulated MAPK signalling [21-25] and selection of individuals with known BRAF-mutated 
tumours [26]. It is, therefore, likely that this class of agents will be used in rationally chosen 
combination therapy.  Combination therapy with trametinib/dabrafenib and 
cobimetinib/vemurafenib for the treatment of BRAF-mutation positive melanoma has been 
shown to improve overall survival, and both these combinations are now licensed [8, 12, 
27].  It has been suggested that resistance to MEK inhibition may occur via up regulation of 
AKT signalling and that combination therapy with both MEK and PI3K inhibitors may be 
beneficial [24, 26], and investigations into this combination therapy continue [28]. The use 
of MEK inhibitors in combination with docetaxel has been investigated in phase II studies in 
melanoma [29] and NSCLC with indications that KRAS mutant NSCLC may be sensitive to the 
combination [30] and a phase III trial is underway to test the efficacy of the combination 
[31]. This Phase I study will inform the further development of WX-554 in phase II trials as a 
single agent and in additional Phase 1 combinatorial trials. It shows how preclinical data and 
modelling in conjunction with PK and PD can be used to help guide an OBD. WX-554 is well 
tolerated at pharmacologically active doses with an attractive once or twice weekly dosing 
schedule and so would be an ideal candidate for combination studies.  
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Figure legends 
Figure 1. 
Phosphorylation of ERK in PBMC lysates following administration of WX-554 and ex-vivo 
stimulation with PMA. WX-554 was administered in a once- weekly (A. Empty circle, 25 mg. 
Square, 50 mg. Triangle 75 mg. Rhombus 100 mg. Filled circle 150 mg), or twice weekly 
regimen (B. Square, 2x25 mg, Rhombus, 2 x 50 mg. Filled circle, 2 x 75 mg). Each data point 
is the mean of the cohort expressed as a percentage of the C1D1 pre-administration sample. 
 
Figure 2. 
Modulation of kinase signalling pathways by treatment with WX-554 in paired tumour 
biopsies from 5 patients in cohort 8 (75 mg twice weekly). Known concentrations of biopsy 
lysates from pre-administration and 8 days post were analysed on MSD 
electrochemiluminescent assays and phosphorylated protein as a percentage of pre-dose 
levels expressed as a ratio of un-phosphorylated protein. No change in the phosphorylation 
as a ratio of total protein (P/T Ratio) of (A) AKT, (B) GSK3, or (C) P70S6K was observed 8 
days after the initial dose of WX-554. In contrast, ERK phosphorylation was decreased in 5/5 
of the tumour biopsy lysates. Each data point represents the ratio for an individual patient 
and the line represents the geometric mean at that timepoint 
 
Figure 3. 
Pharmacokinetics of WX-554. A & B) Concentration time curves of the first administration of 
WX-554 over cycle 1, day 1. WX-554 was administered in a once- weekly (A. Empty circle, 25 
mg. Square, 50 mg. Triangle 75 mg. Rhombus 100 mg. Filled circle 150 mg), or twice weekly 
regimen (B. Circle, 2x25 mg, Square, 2 x 50 mg. Triangle, 2 x 75 mg). C & D) Individual and 
mean AUC  (C) and Cmax (D) on day one. 
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Table 1 Patient demographics 
 
Table 1.  Patient demographics 
Characteristic Total patient (n=41) 
Age  
 Median 63 
 Range 36-77 
Sex   
  Male  28 (68%) 
 Female 13 (32%) 
Performance status  
 0 13 (32%) 
 1 28 (68%) 
Number of previous regimens  
 0 0 
 1 11 (27%) 
 2 14 (34%) 
 >2 16 (39%) 
Tumour type  
 CRC* 10 (24%) 
 NSCLC 7 (17%) 
 Mesothelioma 6 (15%) 
 Oesophageal** 4 (10%) 
 Pancreatic 3 (7%) 
 Cholangiocarcinoma 2 (5%) 
 Cervical 2 (5%) 
 Gastric 1 (2%) 
 GIST 1 (2%) 
 Ampullary carcinoma 1 (2%) 
 Ovarian  1 (2%) 
 Adrenocortical 1 (2%) 
 Squamous carcinoma of the gall 
bladder 
1 (2%) 
 Synovial sarcoma 1 (2%) 
*Including 1 Pouch of Douglas presumed to derive from an anal squamous 
carcinoma. ** One squamous carcinoma of the oesophageal gastric junction 
and three adenocarcinomas.  
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Table 2 
                    
  Table 2) Adverse reactions attributed (described as probably or definitely related) to drug by grade and type that occurred in at least 
10% of the treated population, and all SAEs potentially attributed (described as possibly or probably related) to drug. Include events 
described as probably or definitely attributed to drug. Each event included once at highest grade seen per a patient. 
 
  
     Grade  
  Total    1   2   3   4   5   
  # (%)  # (%)  # (%)  # (%)  # (%)  # (%)  
 Most Frequent                   
 Fatigue/Lethargy 17 (43)  3 (7)  13 (32)  1 (2)        
 Diarrhoea 15 (38)  11 (27)  4 (10)           
 Skin 11 (28)  9 (22)  2 (5)           
 Decreased appetite 7 (18)  4 (10)  3 (7)           
 Nausea 5 (13)  5 (12)              
 Vomiting 5 (13)  5 (12)              
 Abdominal Pain 4 (10)  3 (7)  1 (2)           
                    
 SAE                   
 ALT Increased             1 (2)     
 Anaemia             1 (2)     
 AST Increased          1 (2)        
 Bowel perforation             1 (2)     
 Prolonged QTC       1 (2)           
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 Table 3) Pharmacokinetic parameters during dose escalation of WX-554  
  
 
Frequency Dose  Cohort size t1/2   
Tmax   
Cmax   
Vz/F  
 
Cl/F 
 
AUCinf 
 
 
  (mg)  (n) (h)   (h)    (ng/ml)   (L)   (ml/min)   (h*ng/ml) 
                     
 
   
Mean (SD) 
 
Mean (SD) 
 
Mean (SD) 
 
Mean (SD) 
 
Mean (SD) 
 
Mean (SD) 
                      
 
Day 1 
 
 
QWK 
25 3 20.0 (2.5) 
 
4.7 (1.2) 
 
10.2 (1.6) 
 
3096.4 (604.8) 
 
1781.1 (228.3) 
 
236.4 (28.9) 
 
 
50 3a 14.8 (4.7) 
 
6.0 (2.0) 
 
16.7 (2.5) 
 
3026 (342.0) 
 
2529.8 (1076.2) 
 
362.2 (154.1) 
 
 
75 6 27.4 (13.5) 
 
5.7 (1.5) 
 
23.5 (10.8) 
 
3502.4 (1923.5) 
 
2273.6 (2247.7) 
 
1259.1 (1024.5) 
 
 
100 6 19.0 (8.2) 
 
4.7 (2.1) 
 
29.2 (9.2) 
 
4199.5 (2619.7) 
 
2836.3 (1641.4) 
 
859.8 (706.07) 
 
 
150 6 27.5 (8.6) 
 
4.2 (2.6) 
 
64.8 (27.6) 
 
3104.6 (1568.4) 
 
1512.3 (1649.6) 
 
3104.6 (1924.9) 
                      
 Bis 
25 3b na 
 
4.7 (2.3) 
 
3.0 (2.2) 
 
na 
 
na 
 
na 
 
 
50 3 50.1 (29.5) 
 
4.7 (3.1) 
 
12.2 (2.9) 
 
4573.5 (1275.9) 
 
1211.9 (435.9) 
 
746.2 (248.7) 
 
 
75 9 22.4 (19.7) 
 
4.2 (1.2) 
 
20.3 (9.4) 
 
4804 (2313.7) 
 
3257.3 (1458.0) 
 
631.9 (760.4) 
                     Day 8 
 
 
QWK 
25 3 21.5 (5.3) 
 
4.0 (3.5) 
 
9.9 (0.5) 
 
2937.3 (470.3) 
 
1618.3 (331.8) 
 
265.1 (56.4) 
 
 
50 3 18.1 (1.9) 
 
4.7 (1.2) 
 
18.1 (1.0) 
 
2641.6 (402.4) 
 
1698.7 (365.9) 
 
504.5 (97.2) 
 
 
75 6c 30.9 (14.8) 
 
6.0 (2.2) 
 
25.9 (12.3) 
 
2911.8 (897.3) 
 
1689.4 (1618.2) 
 
1366.2 (912.7) 
 
 
100 6 22.9 (11.8) 
 
4.3 (1.5) 
 
32.3 (18.7) 
 
5885 (6711.5) 
 
2728.8 (1572.9) 
 
958.4 (895.5) 
 
 
150 6 27.7 (9.2) 
 
5.3 (3.0) 
 
70.8 (31.6) 
 
2387.2 (1402.4) 
 
1442.5 (1771.5) 
 
3598.9 (2384.6) 
                      
 Bis 
25 3d 75.0 (16.2) 
 
5.3 (1.2) 
 
4.5 (2.5) 
 
11054.8 (7316.2) 
 
1869.1 (1531.6) 
 
335.6 (275.0) 
 
 
50 3 86.8 (35.4) 
 
6.0 (2.0) 
 
11.7 (5.5) 
 
4858.6 (2098.3) 
 
688.6 (353.6) 
 
1405.6 (577.8) 
 
 
75 9 18.6 (10.0)   3.4 (1.8)   21.9 (9.9)   4094.4 (1758.3)   3119.5 (1906.6)   605.7 (458.8) 
  QWK, Once weekly. Bis, Twice weekly. na, not applicaable. 
a
Mean of two evaluble patients for all parameters other than Tmax and Cmax.  
b
Mean and SD not calculated for all parameters other than Tmax and Cmax as only 
1/3 participants evaluable. 
c
Mean of five evaluble patients for all parameters other than Tmax and Cmax. 
d
Mean of two evaluble patients for all parameters other than Tmax and Cmax. 
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Figure 3
A Phase I pharmacokinetic and pharmacodynamic study of the oral MEK inhibitor, WX-
554, in patients with advanced solid tumours. 
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Table S1 
 
 
 
      
 
 
Table S1) Study participants and cohort size 
 
  
 
Cohort Participants (#) WX-554 (mg/wk) 
 
 
1 4* 25 
 
 
2 3 50 
 
 
3 6 75 
 
 
4 3 2x25 
 
 
5 6 100 
 
 
6 3 2x50 
 
 
7 7 150 
 
 
8 9 2x75 
 
 
*One participant in cohort 1 developed fatal 
bronchopneumonia prior to the first administration of WX-554 
and the cohort was extended to 4 participants. 
 
  
  
 
      
  
 
 
 
Table S2 
 
                                                      
Table S2) Incidence of participants with at least one adverse events for each cohort 
 
WX-554 administered (mg) 
   
 
25 
 
50 
 
75 
 
100 
 
150 
 
2x25 
 
2x50 
 
2x75 
 
Total 
 
# (%)   # (%)   # (%)   # (%)   # (%)   # (%)   # (%)   # (%)   # (%) 
 
                          
Fatigue/lethargy 1 (33.3) 
 
1 (33.3) 
 
4 (66.7) 
 
3 (50) 
 
4 (57.1) 
 
2 (66.7) 
 
3 (100) 
 
7 (77.8) 
 
25 (62.5) 
Diarrhoea 1 (33.3) 
 
1 (33.3) 
 
3 (50) 
 
4 (66.7) 
 
5 (71.4) 
 
1 (33.3) 
 
1 (33.3) 
 
2 (22.2) 
 
18 (45) 
Nausea 
   
1 (33.3) 
 
5 (83.3) 
 
2 (33.3) 
 
2 (28.6) 
 
1 (33.3) 
 
1 (33.3) 
 
4 (44.4) 
 
16 (40) 
Skin 1 (33.3) 
    
2 (33.3) 
 
3 (50) 
 
4 (57.1) 
 
2 (66.7) 
 
1 (33.3) 
 
3 (33.3) 
 
16 (40) 
Vomiting 
   
1 (33.3) 
 
5 (83.3) 
 
2 (33.3) 
 
1 (14.3) 
 
1 (33.3) 
 
1 (33.3) 
 
3 (33.3) 
 
14 (35) 
Decreased appetite 
      
3 (50) 
    
2 (28.6) 
 
2 (66.7) 
 
2 (66.7) 
 
4 (44.4) 
 
13 (32.5) 
Abdominal Pain 1 (33.3) 
 
1 (33.3) 
 
3 (50) 
       
1 (33.3) 
 
2 (66.7) 
 
4 (44.4) 
 
12 (30) 
Infection 1 (33.3) 
 
1 (33.3) 
 
5 (83.3) 
 
1 (16.7) 
    
1 (33.3) 
    
2 (22.2) 
 
11 (27.5) 
Constipation 
   
1 (33.3) 
 
2 (33.3) 
 
2 (33.3) 
 
1 (14.3) 
 
2 (66.7) 
    
1 (11.1) 
 
9 (22.5) 
Anaemia 
   
1 (33.3) 
 
2 (33.3) 
    
2 (28.6) 
 
1 (33.3) 
 
1 (33.3) 
 
1 (11.1) 
 
8 (20) 
Dyspnoea 1 (33.3) 
    
2 (33.3) 
    
1 (14.3) 
 
1 (33.3) 
    
3 (33.3) 
 
8 (20) 
ALP Increased 
      
1 (16.7) 
 
1 (16.7) 
 
1 (14.3) 
 
1 (33.3) 
    
2 (22.2) 
 
6 (15) 
Cough 
      
2 (33.3) 
 
1 (16.7) 
 
1 (14.3) 
 
1 (33.3) 
    
1 (11.1) 
 
6 (15) 
ALT Increased 
      
1 (16.7) 
 
1 (16.7) 
 
1 (14.3) 
 
1 (33.3) 
    
1 (11.1) 
 
5 (12.5) 
Bilirubin 
      
1 (16.7) 
 
1 (16.7) 
 
1 (14.3) 
       
2 (22.2) 
 
5 (12.5) 
Dyspepsia 
   
1 (33.3) 
 
1 (16.7) 
    
1 (14.3) 
  
(0) 
 
1 (33.3) 
 
1 (11.1) 
 
5 (12.5) 
AST Increased 
      
1 (16.7) 
 
1 (16.7) 
    
1 (33.3) 
    
1 (11.1) 
 
4 (10) 
CRP increased                         1 (14.3)   1 (33.3)         2 (22.2)   4 (10) 
 
